UNSPSC 51122803: Itrocainide

This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 79EDP2VHY8. European Medicines Agency schedules Itrocainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08355MIG. Itrocainide generally arises in the molecular formula C23H27N3O.

UNSPSC 51122803 Itrocainide is a Commodity code for a specific antiarrhythmic pharmaceutical. State and local governments procure this medication primarily through emergency medical services and public health programs — specifically, fire rescue departments and pharmacy benefit programs use it as part of advanced life support protocols and formulary management. The issuing bodies span municipal fire departments, state health agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions and member organizations.

Activity under this code is concentrated in Florida and Minnesota, with emerging interest from Texas state health agencies exploring direct-to-manufacturer pharmacy programs. The City of Tampa's Fire Rescue Purchasing Department posted an IFB (Bid No. 26P00188) on April 24, 2026, for Advanced Life Support Medications including itrocainide and related cardiac agents, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the contract offers a one-year initial term with two optional one-year renewals and carries a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with products required to be available by May 15, 2026, and a two-year initial contract term. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in early April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative focused on direct-to-manufacturer prescription programs, signaling state-level interest in alternative pharmacy procurement models beyond traditional PBM and GPO channels.